DA Davidson lowered the firm’s price target on Teladoc to $8 from $12 and keeps a Neutral rating on the shares. The firm cites the company withdrawing its top- and bottom-line guidance for 2024, as well as its three-year financial targets, in response to acute uncertainty in its Betterhelp business, though the Integrated Care segment continues to be Teladoc’s greatest strength, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- TDOC Earnings: Teladoc Health Stock Crashes on Mixed Q2 Results, Withdraws Outlook
- Options Volatility and Implied Earnings Moves Today, July 31, 2024
- Options Volatility and Implied Earnings Moves This Week, July 29 – August 02, 2024
- TDOC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Teladoc call volume above normal and directionally bullish
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue